Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients
Tuesday, December 5, 2017 BiopharmaWatch Research 1 min read
Key Takeaway: Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers
Full Press Release Details
Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients.